Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 20-Mar-23 4:29 PM View:  | Cohen Ron President and CEO Director | Acorda Therapeutics, Inc. (ACOR) | 17-Mar-23 | Purchase | 10,000 | $0.65 | $6,500.00 | 7% 139.76K to 149.76K | |
| 20-Mar-23 4:29 PM View: | Cohen Ron President and CEO Director | Acorda Therapeutics, Inc. (ACOR) | 16-Mar-23 | Private Purchase | 10,156 | $0.60 | $6,093.60 | 8% 129.6K to 139.76K | |
| 07-Sep-22 7:59 AM View: | Clem Kerry M Chief Commercial Officer | Acorda Therapeutics, Inc. (ACOR) | 03-Sep-22 | Payment of Exercise | 1,511 | $0.40 | $601.38 | (13%) 11.59K to 10.08K | |
| 07-Sep-22 8:00 AM View: | Sabella Lauren M Chief Operating Officer | Acorda Therapeutics, Inc. (ACOR) | 03-Sep-22 | Payment of Exercise | 1,511 | $0.40 | $601.38 | (12%) 12.22K to 10.71K | |
| 21-Mar-22 4:26 PM View: | Cohen Ron President and CEO Director | Acorda Therapeutics, Inc. (ACOR) | 17-Mar-22 | Sale | 2,289 | $1.70 | $3,894.50 | (2%) 131.89K to 129.6K | |
| 08-Sep-21 7:19 AM View: | Cohen Ron President and CEO Director | Acorda Therapeutics, Inc. (ACOR) | 03-Sep-21 | Payment of Exercise | 3,940 | $4.38 | $17,257.20 | (3%) 135.83K to 131.89K | 4% |
| 08-Sep-21 7:20 AM View: | Morales Robert Interim PAO & PFO | Acorda Therapeutics, Inc. (ACOR) | 03-Sep-21 | Payment of Exercise | 448 | $4.38 | $1,962.24 | (9%) 4.87K to 4.42K | 4% |
| 08-Sep-21 7:21 AM View: | Sabella Lauren M Chief Commercial Officer | Acorda Therapeutics, Inc. (ACOR) | 03-Sep-21 | Payment of Exercise | 1,511 | $4.38 | $6,618.18 | (11%) 13.73K to 12.22K | 4% |
| 05-Mar-21 6:36 PM View: | Sabella Lauren M Chief Commercial Officer | Acorda Therapeutics, Inc. (ACOR) | 03-Mar-21 | Grant | 11,125 | -- | -- | 427% 2.61K to 13.73K | |
| 05-Mar-21 6:34 PM View: | Cohen Ron President and CEO Director | Acorda Therapeutics, Inc. (ACOR) | 03-Mar-21 | Grant | 29,000 | -- | -- | 27% 106.83K to 135.83K | |
| 05-Mar-21 6:33 PM View: | Blank Burkhard CMO and Head of R&D | Acorda Therapeutics, Inc. (ACOR) | 03-Mar-21 | Grant | 11,125 | -- | -- | 150% 7.4K to 18.53K | |
| 03-Dec-20 7:58 AM View: | Lawrence David Chief, Bus. Ops & PAO | Acorda Therapeutics, Inc. (ACOR) | 01-Dec-20 | Payment of Exercise | 1,141 | $0.65 | $737.54 | (8%) 14.95K to 13.81K | (10%) |
| 12-Nov-20 7:43 AM View: | Lawrence David Chief, Bus. Ops & PAO | Acorda Therapeutics, Inc. (ACOR) | 09-Nov-20 | Payment of Exercise | 1,024 | $0.86 | $880.54 | (6%) 15.98K to 14.95K | 19% |
| 21-Sep-20 8:35 AM View: | Sabella Lauren M Chief Commercial Officer | Acorda Therapeutics, Inc. (ACOR) | 17-Sep-20 | Grant | 3,015 | -- | -- | 24% 12.62K to 15.64K | |
| 21-Sep-20 8:29 AM View: | Cohen Ron President and CEO Director | Acorda Therapeutics, Inc. (ACOR) | 17-Sep-20 | Grant | 8,543 | -- | -- | 1% 632.44K to 640.98K | |
| 21-Sep-20 8:26 AM View: | Blank Burkhard CMO and Head of R&D | Acorda Therapeutics, Inc. (ACOR) | 17-Sep-20 | Grant | 3,015 | -- | -- | 7% 41.4K to 44.41K | |
| 21-Sep-20 8:31 AM View: | Lawrence David Chief, Bus. Ops & PAO | Acorda Therapeutics, Inc. (ACOR) | 17-Sep-20 | Grant | 3,015 | -- | -- | 23% 12.96K to 15.98K | |
| 04-Dec-19 7:51 AM View: | Sabella Lauren M Chief Commercial Officer | Acorda Therapeutics, Inc. (ACOR) | 02-Dec-19 | Market Sale (Planned) | 1,513 | $1.60 | $2,421.10 | (11%) 14.14K to 12.62K | 54% |
| 04-Dec-19 7:49 AM View: | Lawrence David Chief, Bus. Ops & PAO | Acorda Therapeutics, Inc. (ACOR) | 02-Dec-19 | Market Sale (Planned) | 1,176 | $1.60 | $1,879.95 | (8%) 14.14K to 12.96K | 54% |
| 04-Dec-19 7:47 AM View: | Cohen Ron President and CEO Director | Acorda Therapeutics, Inc. (ACOR) | 02-Dec-19 | Market Sale (Planned) | 4,699 | $1.60 | $7,505.24 | (< 1%) 637.14K to 632.44K | 54% |
| 04-Dec-19 7:53 AM View: | Wasman Jane President, Intl and GC | Acorda Therapeutics, Inc. (ACOR) | 02-Dec-19 | Market Sale (Planned) | 2,227 | $1.60 | $3,552.73 | (2%) 119.65K to 117.42K | 54% |
| 12-Mar-19 4:13 PM View: | Cohen Ron President and CEO Director | Acorda Therapeutics, Inc. (ACOR) | 08-Mar-19 | Grant | 25,629 | -- | -- | 4% 611.51K to 637.14K | |
| 12-Mar-19 4:15 PM View: | Hindman Andrew A. Chief Business Officer | Acorda Therapeutics, Inc. (ACOR) | 08-Mar-19 | Grant | 9,045 | -- | -- | 137% 6.59K to 15.64K | |
| 12-Mar-19 4:11 PM View: | Blank Burkhard CMO and Head of R&D | Acorda Therapeutics, Inc. (ACOR) | 08-Mar-19 | Grant | 9,045 | -- | -- | 28% 32.35K to 41.4K | |
| 12-Mar-19 4:25 PM View: | Wasman Jane President, Intl and GC | Acorda Therapeutics, Inc. (ACOR) | 08-Mar-19 | Grant | 12,813 | -- | -- | 12% 106.83K to 119.65K | |
| 12-Mar-19 4:21 PM View: | Lawrence David Chief, Bus. Ops & PAO | Acorda Therapeutics, Inc. (ACOR) | 08-Mar-19 | Grant | 9,045 | -- | -- | 178% 5.09K to 14.14K | |
| 12-Mar-19 4:23 PM View: | Sabella Lauren M Chief Commercial Officer | Acorda Therapeutics, Inc. (ACOR) | 08-Mar-19 | Grant | 9,045 | -- | -- | 178% 5.09K to 14.14K | |
| 25-Feb-19 4:17 PM View: | Lawrence David Chief, Bus. Ops & PAO | Acorda Therapeutics, Inc. (ACOR) | 22-Feb-19 | Market Sale | 761 | $13.18 | $10,028.30 | (13%) 5.85K to 5.09K | 94% |
| 25-Feb-19 4:19 PM View: | Sabella Lauren M Chief Commercial Officer | Acorda Therapeutics, Inc. (ACOR) | 22-Feb-19 | Market Sale | 761 | $13.18 | $10,028.20 | (13%) 5.85K to 5.09K | 94% |
| 25-Feb-19 4:15 PM View: | Hindman Andrew A. Chief Business Officer | Acorda Therapeutics, Inc. (ACOR) | 21-Feb-19 | Payment of Exercise | 877 | $13.38 | $11,734.30 | (12%) 7.47K to 6.59K | 95% |
| 25-Feb-19 4:21 PM View: | Wasman Jane President, Intl and GC | Acorda Therapeutics, Inc. (ACOR) | 21-Feb-19 | Payment of Exercise | 953 | $13.38 | $12,751.10 | (< 1%) 107.79K to 106.83K | 95% |
| 25-Feb-19 4:11 PM View: | Cohen Ron President and CEO Director | Acorda Therapeutics, Inc. (ACOR) | 21-Feb-19 | Payment of Exercise | 2,027 | $13.38 | $27,121.30 | (< 1%) 613.53K to 611.51K | 95% |
| 01-Feb-19 4:28 PM View: | Scopia Management Inc 10% Owner | Acorda Therapeutics, Inc. (ACOR) | 30-Jan-19 | Market Sale | 7,000 | $16.01 | $112,039.00 | (< 1%) 4.76M to 4.75M | 95% |
| 28-Jan-19 4:09 PM View: | Scopia Management Inc 10% Owner | Acorda Therapeutics, Inc. (ACOR) | 25-Jan-19 | Market Sale | 2,401 | $16.00 | $38,416.00 | (< 1%) 4.76M to 4.76M | 95% |
| 28-Jan-19 4:09 PM View: | Scopia Management Inc 10% Owner | Acorda Therapeutics, Inc. (ACOR) | 24-Jan-19 | Market Sale | 8,600 | $16.03 | $137,851.00 | (< 1%) 4.77M to 4.76M | 95% |
| 24-Jan-19 4:06 PM View: | Scopia Management Inc 10% Owner | Acorda Therapeutics, Inc. (ACOR) | 23-Jan-19 | Market Sale | 45,898 | $16.01 | $734,942.00 | (< 1%) 4.81M to 4.77M | 95% |
| 24-Jan-19 4:06 PM View: | Scopia Management Inc 10% Owner | Acorda Therapeutics, Inc. (ACOR) | 22-Jan-19 | Market Sale | 51,945 | $16.02 | $831,972.00 | (1%) 4.87M to 4.81M | 95% |
| 22-Jan-19 4:18 PM View: | Scopia Management Inc 10% Owner | Acorda Therapeutics, Inc. (ACOR) | 18-Jan-19 | Market Sale | 39,358 | $16.24 | $639,327.00 | (< 1%) 4.91M to 4.87M | 96% |
| 22-Jan-19 4:18 PM View: | Scopia Management Inc 10% Owner | Acorda Therapeutics, Inc. (ACOR) | 17-Jan-19 | Market Sale | 100,000 | $16.86 | $1,685,550.00 | (2%) 5.01M to 4.91M | 96% |
| 17-Jan-19 4:06 PM View: | Scopia Management Inc 10% Owner | Acorda Therapeutics, Inc. (ACOR) | 16-Jan-19 | Market Sale | 91,650 | $16.94 | $1,552,410.00 | (2%) 5.1M to 5.01M | 96% |
| 17-Jan-19 4:06 PM View: | Scopia Management Inc 10% Owner | Acorda Therapeutics, Inc. (ACOR) | 15-Jan-19 | Market Sale | 1,700 | $16.60 | $28,223.10 | (< 1%) 5.1M to 5.1M | 96% |
| 15-Jan-19 4:32 PM View: | Scopia Management Inc 10% Owner | Acorda Therapeutics, Inc. (ACOR) | 11-Jan-19 | Market Sale | 40,392 | $17.40 | $702,788.00 | (< 1%) 5.14M to 5.1M | 96% |
| 11-Jan-19 4:18 PM View: | Scopia Management Inc 10% Owner | Acorda Therapeutics, Inc. (ACOR) | 10-Jan-19 | Market Sale | 87,491 | $17.29 | $1,512,730.00 | (2%) 5.23M to 5.14M | 96% |
| 11-Jan-19 4:18 PM View: | Scopia Management Inc 10% Owner | Acorda Therapeutics, Inc. (ACOR) | 09-Jan-19 | Market Sale | 75,000 | $17.05 | $1,278,700.00 | (1%) 5.3M to 5.23M | 96% |
| 09-Jan-19 4:22 PM View: | Scopia Management Inc 10% Owner | Acorda Therapeutics, Inc. (ACOR) | 08-Jan-19 | Market Sale | 59,174 | $16.24 | $960,927.00 | (1%) 5.36M to 5.3M | 95% |
| 09-Jan-19 4:22 PM View: | Scopia Management Inc 10% Owner | Acorda Therapeutics, Inc. (ACOR) | 07-Jan-19 | Market Sale | 75,000 | $16.56 | $1,241,740.00 | (1%) 5.44M to 5.36M | 96% |
| 07-Jan-19 4:08 PM View: | Scopia Management Inc 10% Owner | Acorda Therapeutics, Inc. (ACOR) | 04-Jan-19 | Market Sale | 31,591 | $16.61 | $524,714.00 | (< 1%) 5.47M to 5.44M | 96% |
| 07-Jan-19 4:08 PM View: | Scopia Management Inc 10% Owner | Acorda Therapeutics, Inc. (ACOR) | 03-Jan-19 | Market Sale | 23,616 | $15.74 | $371,645.00 | (< 1%) 5.49M to 5.47M | 95% |
| 02-Jan-19 4:11 PM View: | Scopia Management Inc 10% Owner | Acorda Therapeutics, Inc. (ACOR) | 28-Dec-18 | Market Sale | 52,891 | $14.99 | $792,752.00 | (< 1%) 5.54M to 5.49M | 95% |
| 28-Dec-18 4:11 PM View: | Scopia Management Inc 10% Owner | Acorda Therapeutics, Inc. (ACOR) | 27-Dec-18 | Market Sale | 50,000 | $14.66 | $732,760.00 | (< 1%) 5.59M to 5.54M | 95% |
